FDA authorizes marketing of novel device intended to reduce snoring and mild obstructive sleep apnea in patients 18 years and older
2021-02-05
The U.S. Food and Drug Administration authorized marketing of a new prescription only device intended to reduce snoring and mild obstructive sleep apnea. Unlike devices used while patients sleep, this is the first device used while awake that is intended to improve tongue muscle function, which in time can helpContinue Reading
